ទំព័រដើម › មហារីកសួត › ម៉ាសាឈូសេត › Boston
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកសួត នៅក្នុង Boston, MA
ការសិក្សាចំនួន 62 សម្រាប់ មហារីកសួត កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Boston (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Tufts Medical Center, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Dana-Farber Cancer Institute, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Research Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
កំពុងជ្រើសរើសដំណាក់កាល 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Massachusetts General Hospital, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
កំពុងជ្រើសរើស
- Brigham and Women's Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital Cancer Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
កំពុងជ្រើសរើស
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
កំពុងជ្រើសរើស
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Prediction Augmented Screening Initiative
កំពុងជ្រើសរើស
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
កំពុងជ្រើសរើស
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
កំពុងជ្រើសរើស
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
កំពុងជ្រើសរើស
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana-Farber Cancer Institute, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
កំពុងជ្រើសរើសដំណាក់កាល 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
កំពុងជ្រើសរើសដំណាក់កាល 1ស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital Cancer Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
កំពុងជ្រើសរើស
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
កំពុងជ្រើសរើស
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Image Guided VATS vs. VATS Resection
កំពុងជ្រើសរើស
- Brigham and Women's Hospital, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Molecular and Genetic Analysis of Lung Cancer
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Massachusetts General Hospital, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Boston University Medical Center, Boston
ការសាកល្បងសម្រាប់ មហារីកសួត នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 78
- New York City, NYការសិក្សា 60
- Los Angeles, CAការសិក្សា 45
- Washington, DCការសិក្សា 41
- Arlington, VAការសិក្សា 41
- Chicago, ILការសិក្សា 41
- Nashville, TNការសិក្សា 40
- Baltimore, MDការសិក្សា 40
- St. Louis, MOការសិក្សា 39
- Columbus, OHការសិក្សា 37
- Philadelphia, PAការសិក្សា 36
- Seattle, WAការសិក្សា 33
ការសិក្សាផ្សេងទៀតនៅក្នុង Boston
- មហារីកទ្រូងការសិក្សា 111
- Non-Small Cell Lung Cancerការសិក្សា 90
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 86
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 63
- មហារីកដែលរីករាលដាលការសិក្សា 63
- មហារីកស៊ុតការសិក្សា 61
- មហារីកតូចការសិក្សា 59
- ភាពសោកសៅការសិក្សា 52
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 50
- បេះដូងខ្សោយការសិក្សា 44
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 44
- មហារីកតំបក់ការសិក្សា 43
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។